Key Details
Price
$1.64Annual ROE
309.83%Beta
0.00Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
July 12, 2023Analyst ratings
Recent major analysts updates
Screeners with AXDX included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.92 per share a year ago.
TUCSON, Ariz. , Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m.
AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.
An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samples TUCSON, Ariz. , Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper® CA System (MBT-CA System) and MBT-CA Sepsityper® software extension.
Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and CEO David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good day. And welcome to the Accelerate Diagnostics Incorporated Second Quarter 2024 Results Conference Call.
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $2.36 per share a year ago.
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024.
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call today, Thursday, August 8, 2024, at 4:30 p.m.
FAQ
- What is the primary business of Accelerate Diagnostics?
- What is the ticker symbol for Accelerate Diagnostics?
- Does Accelerate Diagnostics pay dividends?
- What sector is Accelerate Diagnostics in?
- What industry is Accelerate Diagnostics in?
- What country is Accelerate Diagnostics based in?
- When did Accelerate Diagnostics go public?
- Is Accelerate Diagnostics in the S&P 500?
- Is Accelerate Diagnostics in the NASDAQ 100?
- Is Accelerate Diagnostics in the Dow Jones?
- When was Accelerate Diagnostics's last earnings report?
- When does Accelerate Diagnostics report earnings?
- Should I buy Accelerate Diagnostics stock now?